Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects…(FOCAL) | Phase 2 | terminated | Dec 17, 2014 | AVEO Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | Phase 3 | withdrawn | Dec 19, 2007 | CTI BioPharma | not stated | Not stated |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Aug 25, 2010 | Herlev Hospital | Dose over MTD reached | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02642939 | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic… | Phase 2 | terminated | Dec 30, 2015 | Check, Jerome H., M.D., Ph.D. | Lack of enrollment | Enrollment / accrual |
| NCT03945227 | Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus… | Phase 2 | withdrawn | May 10, 2019 | Yonsei University | Due to the delay in the study shceduled, due to the start of competitive study and the approval of… | Safety / toxicity |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT02145078 | Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV… | N/A | terminated | May 22, 2014 | Barbara Ann Karmanos Cancer Institute | Slow accrual. | Enrollment / accrual |
| NCT01532362 | Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T… | N/A | terminated | Feb 14, 2012 | Jonsson Comprehensive Cancer Center | Drug sponsor stopped drug manufacture due to toxicity issues from other studies | Safety / toxicity |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC)… | Phase 1 | terminated | Apr 17, 2017 | EMD Serono Research & Development Institute, Inc. | Enrollment in the study was prematurely terminated due to recruitment challenges and not due to… | Safety / toxicity |
| NCT03382912 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line…(Cypress 2) | Phase 2 | terminated | Dec 26, 2017 | Eli Lilly and Company | The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit… | Other (stated, no rule matched) |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum…(PINNACLE) | Phase 1 / Phase 2 | terminated | May 22, 2013 | OncoMed Pharmaceuticals, Inc. | OMP-59R5 did not improve PFS. | Other (stated, no rule matched) |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT02147990 | Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant…(NSCLC) | Phase 2 | terminated | May 28, 2014 | Clovis Oncology, Inc. | Sponsor discontinued development of CO-1686 for NSCLC. | Other (stated, no rule matched) |
| NCT04510415 | Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI | Phase 1 | terminated | Aug 12, 2020 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in… | Phase 1 / Phase 2 | terminated | Feb 6, 2012 | Clovis Oncology, Inc. | not stated | Not stated |
| NCT03607682 | Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With… | N/A | terminated | Jul 31, 2018 | Vanderbilt-Ingram Cancer Center | PI left institution and loss of funding | Investigator |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT02451865 | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV… | Phase 1 | withdrawn | May 22, 2015 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT02412371 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With… | Phase 1 / Phase 2 | terminated | Apr 9, 2015 | AbbVie | Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable… | Other (stated, no rule matched) |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or… | Phase 1 / Phase 2 | terminated | Jan 20, 2017 | AbbVie | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2. | Safety / toxicity |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab…(RATIONALE001) | Phase 3 | terminated | Nov 19, 2018 | Celgene | BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound,… | Other (stated, no rule matched) |
| NCT00840749 | Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell…(STARS) | N/A | terminated | Feb 10, 2009 | Accuray Incorporated | Lack of enrollment | Enrollment / accrual |
| NCT02193152 | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Phase 2 | terminated | Jul 17, 2014 | Washington University School of Medicine | Terminated by sponsor | Other (stated, no rule matched) |
| NCT01857271 | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell…(EVENT) | Phase 2 | terminated | May 20, 2013 | Albert Einstein College of Medicine | low accrual | Enrollment / accrual |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating… | Phase 2 | terminated | Mar 4, 2013 | University of Chicago | Due to lack of activity and slow accrual | Enrollment / accrual |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy…(IDA) | Phase 3 | terminated | Dec 9, 2013 | Norwegian University of Science and Technology | Poor enrollment due to the introduction of immunotherapy | Enrollment / accrual |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants… | Phase 2 | withdrawn | Jul 13, 2016 | Eli Lilly and Company | To pursue broader program objectives in oncology. | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small… | Phase 3 | withdrawn | Dec 18, 2019 | Incyte Corporation | Sponsor Strategic/Business Decision | Sponsor / business decision |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | Phase 2 | terminated | Jan 26, 2018 | Agenus Inc. | Trial will not proceed due to changes in the treatment landscape. | Other (stated, no rule matched) |
| NCT03713099 | NEUWAVE Flexible Probe Study #2 | N/A | withdrawn | Oct 19, 2018 | Ethicon, Inc. | Changed study design prior to any patients enrolled. | Enrollment / accrual |
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | Phase 2 | terminated | Jan 11, 2007 | NewLink Genetics Corporation | Enrollment goals unable to be reached. | Enrollment / accrual |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | terminated | Jan 24, 2013 | NewLink Genetics Corporation | not stated | Not stated |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated…(CARACTER) | N/A | terminated | Mar 13, 2013 | Amphia Hospital | bad taste of Caphosol - early stop of intake by patients | Other (stated, no rule matched) |
| NCT03574220 | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung… | Early Phase 1 | withdrawn | Jun 29, 2018 | Case Comprehensive Cancer Center | No accrual - closed by PRMC | Enrollment / accrual |
| NCT03674450 | Lung Heart Rate Variability(HRV) | N/A | withdrawn | Sep 17, 2018 | Abramson Cancer Center at Penn Medicine | This study never enrolled any subjects. It was terminated due to staffing and technology changes. | Enrollment / accrual |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in… | Phase 2 | terminated | May 22, 2015 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous… | Phase 1 | withdrawn | Jun 28, 2011 | Mayo Clinic | lack of access to study drug | Other (stated, no rule matched) |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as… | Phase 2 / Phase 3 | terminated | Oct 6, 2016 | SWOG Cancer Research Network | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. | Sponsor / business decision |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent… | Phase 1 | withdrawn | Jan 8, 2009 | University of Maryland, Baltimore | There was no patient accrual nor study activity due to inability to fund PFTs. | Enrollment / accrual |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable -… | Phase 2 | terminated | Jul 2, 2018 | Montefiore Medical Center | Poor accrual | Enrollment / accrual |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic… | Phase 1 | terminated | Jul 9, 2018 | Regeneron Pharmaceuticals | Program reprioritization | Other (stated, no rule matched) |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients… | Phase 1 | terminated | Jun 30, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | Phase 2 | terminated | Oct 30, 2012 | Mayo Clinic | Poor accrual and funding ended | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 23, 2020source: clinicaltrials